<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The objective of this study was to assess <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) medications in relation to <z:hpo ids='HP_0002665'>lymphoma</z:hpo> risk </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Information on IBD and relevant medications and other utilization was obtained from the Kaiser Permanente IBD Registry, 1996-2009 </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> cases were ascertained from the Kaiser Permanente <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registry </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> incidence was compared between the IBD cohort and the general Kaiser Permanente population </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of the 16,023 IBD patients without human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus followed an average 5.8 years, 43 developed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>IBD patients with and without <z:hpo ids='HP_0002665'>lymphoma</z:hpo> did not differ with respect to past IBD-related visits, procedures, or tests </plain></SENT>
<SENT sid="6" pm="."><plain>The standardized incidence rate ratio (SIRR) for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> among IBD patients with no dispensing of <z:chebi fb="0" ids="35666">thiopurine</z:chebi> or anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) was 1.0 (95% confidence interval (CI): 0.96-1.1) </plain></SENT>
<SENT sid="7" pm="."><plain>Of the 21,282 person-years involving exposure to <z:chebi fb="0" ids="35666">thiopurine</z:chebi> or anti-TNF, 81% involved <z:chebi fb="0" ids="35666">thiopurine</z:chebi> alone; 3%, anti-TNF alone; and 16%, combination therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Among patients with <z:chebi fb="0" ids="35666">thiopurine</z:chebi> but not anti-TNF dispensings, the SIRR was 0.3 (95% CI: 0.2-0.4) for past use and 1.4 for current use (95% CI: 1.2-2.7) </plain></SENT>
<SENT sid="9" pm="."><plain>Among patients with dispensing of anti-TNF (with and without <z:chebi fb="0" ids="35666">thiopurine</z:chebi>), the SIRR was 5.5 for past use (95% CI: 4.5-6.6) and 4.4 for current use (95% CI: 3.4-5.4) </plain></SENT>
<SENT sid="10" pm="."><plain>The most common <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes were diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (44%), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (14%), and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (12%) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our study provides evidence that IBD alone is not associated with the risk of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Use of anti-TNF with <z:chebi fb="0" ids="35666">thiopurine</z:chebi> and current use of <z:chebi fb="0" ids="35666">thiopurine</z:chebi> alone were associated with increased risk, although the effect of disease severity merits further evaluation </plain></SENT>
</text></document>